Paroxysmal Nocturnal Hemoglobinuria Treatment and Management
Paroxysmal nocturnal hemoglobinuria (PNH) is a chronic condition characterized by the destruction of red blood cells, known as hemolysis, which leads to anemia—a state where red blood cells cannot carry sufficient oxygen to body tissues. Beyond anemia, PNH is associated with blood clots (thrombosis) and impaired bone marrow function, which prevents the body from producing enough blood cells.
Managing PNH requires a combination of acute crisis intervention, long-term monitoring, and targeted pharmacological therapies designed to inhibit the complement system, a part of the immune system that mistakenly attacks red blood cells in PNH patients.
Key Facts
- Complement Inhibition: Modern PNH treatments focus on blocking specific proteins (C3, C5, Factor B, or Factor D) to stop red blood cell destruction.
- Thrombosis Risk: Patients with a large clone (50% of white blood cells type III) are at high risk for blood clots and may require preventive warfarin therapy.
- Monitoring: Patients with small clones are typically monitored via flow cytometry every six months.
- Iron Balance: While iron deficiency can occur due to urinary loss, iron therapy must be handled carefully as it can increase the production of PNH cells and worsen hemolysis.
Managing Acute Attacks and Long-Term Care
Acute Hemolytic Crises
Treatment for acute attacks varies. There is ongoing disagreement regarding whether steroids, such as prednisolone, effectively decrease the severity of hemolytic crises. Transfusion therapy is often employed not only to correct significant anemia but also to suppress the bone marrow's production of PNH cells, thereby indirectly reducing hemolysis.
Iron deficiency often develops over time due to losses in the urine. While this may require treatment, clinicians must be cautious; iron therapy can potentially lead to increased hemolysis by stimulating the production of more PNH cells.
Chronic Management and Thrombosis
For patients with a small clone and minimal symptoms, flow cytometry is used every six months to track disease severity and complication risks. However, for those with a large clone (defined as 50% of white blood cells being type III), preventive treatment with warfarin is used to decrease the high risk of thrombosis.
If a thrombotic episode occurs, it is treated using standard protocols. Because PNH is a persisting underlying cause, long-term treatment with warfarin or similar anticoagulants is typically necessary following an episode.
Targeted Pharmacological Treatments
The primary goal of PNH medication is to inhibit the complement system to prevent intravascular hemolysis (the breakdown of red blood cells within the bloodstream).
C5 Inhibitors
Eculizumab (Soliris) was the first approved terminal complement inhibitor. It is a recombinant humanized monoclonal antibody administered via intravenous infusion. By binding to the complement C5 protein, it reduces red blood cell destruction and the need for blood transfusions, though it does not appear to affect overall mortality. Common side effects include headache, nasopharyngitis, back pain, and nausea.
Crovalimab (Piasky) is a more recent monoclonal antibody and C5 inhibitor developed by Roche/Genentech. It received regulatory approval in China (February 2024), Japan (April 2024), the United States (June 2024), and the European Union (August 2024).
C3 and Alternative Pathway Inhibitors
Pegcetacoplan (Empaveli) is a first-in-class treatment that binds to and inhibits complement protein C3. Approved in the US in May 2021, it is also used for C3 glomerulopathy and membranoproliferative glomerulonephritis. The VALIANT trial demonstrated its benefits in treating C3 glomerulopathy, a condition that leads to kidney failure in roughly 50% of patients within 5–10 years. Common side effects include injection-site reactions, infections, and fatigue.
Danicopan (Voydeya) is a first-in-class complement inhibitor that reversibly binds to factor D. This prevents hemolysis mediated by the alternative pathway and stops the deposition of C3 proteins on red blood cells. It was approved in Japan (January 2024), the US (March 2024), and the EU (April 2024). Side effects may include fever, headache, and increased liver enzymes.
Iptacopan (Fabhalta), developed by Novartis, is an oral complement factor B inhibitor used for PNH and proteinuria. It was approved in the US in December 2023 and the EU in May 2024.
| Medication | Target | Administration | Key Feature |
|---|---|---|---|
| Eculizumab | C5 | Intravenous | First approved terminal inhibitor |
| Crovalimab | C5 | Not specified | Recent 2024 global approvals |
| Pegcetacoplan | C3 | Not specified | First C3 inhibitor; treats kidney complications |
| Danicopan | Factor D | Not specified | Prevents alternative pathway hemolysis |
| Iptacopan | Factor B | Oral | First-in-class oral inhibitor |
Frequently Asked Questions
What is the main goal of PNH medications?
The primary goal is to inhibit the complement system—specifically proteins like C3, C5, Factor B, or Factor D—to prevent the immune system from destroying red blood cells (intravascular hemolysis).
Why is warfarin used in some PNH patients?
Warfarin is used as a preventive measure to reduce the high risk of thrombosis (blood clots), particularly in patients with a large clone where 50% of white blood cells are type III.
Can iron supplements be dangerous for PNH patients?
Yes, while iron deficiency is common due to urinary loss, iron therapy can stimulate the production of more PNH cells, which may lead to increased hemolysis.
How is PNH monitored in patients with mild symptoms?
Patients with a small clone and few complications are typically monitored every six months using flow cytometry to assess the severity of the disease and the risk of complications.
What makes Pegcetacoplan different from Eculizumab?
While Eculizumab targets the C5 protein, Pegcetacoplan is the first treatment to bind to and inhibit the C3 protein, and it also has applications in treating specific kidney diseases like C3 glomerulopathy.